FDA Accepts Larotrectinib New Drug Application and Grants Priority Review
Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) submitted by its collaboration partner Loxo Oncology, Inc. (NASDAQ: LOXO),…
Read More...
Read More...